Health outcomes, education, healthcare delivery and quality – 3063. Cost-effectiveness of immunotherapy for children with atopic dermatitis

Methods There were examined 94 Ch aged 3-18 years with AD and duration of disease 1-15 years. Patients underwent the standard general clinical and immunological and allergy survey. The treatment consisted of 2 stages: traditional therapy (TT) for reducing disease complications, and IT. Patients were divided in 3 groups: I group (n=30) received stepped therapy with immune response-modulating agent (IRMA) in course dose of 20mg; II group (n=31) was treated with parenteral accelerated allergenspecific immunotherapy (APAI); III group (n=33) received combination of IT CIT (IRMA+APAI) on the fast track scheme. Pharmacoeconomic assessments were performed using cost-effectiveness analysis.